Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke

被引:24
作者
Uyttenboogaart, M.
Vroomen, P. C. A. J.
Stewart, R. E.
De Keyser, J.
Luijckx, G. J.
机构
[1] Univ Groningen, Med Ctr, Dept Neurol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Med Ctr, Dept Hlth Sci, Groningen, Netherlands
关键词
safety; stroke; thrombolysis; time window;
D O I
10.1016/j.jns.2006.12.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The administration of tissue plasminogen activator (t-PA) has been proven effective for ischemic stroke within 3 h after onset. A pooled-analysis of six trials showed that intravenous t-PA still improves outcome when given between 3 to 4.5 h after stroke onset. On the basis of this pooled analysis, t-PA was also routinely offered to our patients between 3-4.5 h. We report the safety and clinical features of this group together with the features of the group given t-PA within 3 h. Methods: Prospectively patient characteristics, stroke severity, stroke subtype, incidence of symptomatic intracerebral hemorrhage (SICH), in-hospital mortality, and 3-months modified Rankin Scale scores (mRS) were registered. Data was analyzed separately for patients treated within 3 h (early group) and those treated between 3-4.5 h (late group). Results: Among 176 patients who underwent intravenous thrombolysis, 101 were treated in the early group and 75 in the late group. Six (5.9%; 95% CI 2.8%-12.3%) patients in the early group and 4 (5.3%; 95% CI 2.2%-12.9%) in the late group developed SICH (p=1.0). In the early group 13 (12.9%; 95% CI 7.7%-20.8%) patients died within 7 days after admission, compared to 5 (6.7%; 95% CI 3.0%-14.7%) in the late group (p=0.179). In the early group 44 (43.6%; 95% CI 43.3%-53.3%) were independent (mRS <= 2) at three months, compared to 36 (48.0%; 95% CI 37.0%-59.1%) in the late group (p=0.559). Conclusion: Our data show no trend of decreased safety of thrombolysis beyond 3 h. Due to a small sample size a harmful effect cannot be excluded but seems unlikely. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 24 条
  • [1] Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study
    Albers, GW
    Bates, VE
    Clark, WM
    Bell, R
    Verro, P
    Hamilton, SA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09): : 1145 - 1150
  • [2] CLASSIFICATION AND NATURAL-HISTORY OF CLINICALLY IDENTIFIABLE SUBTYPES OF CEREBRAL INFARCTION
    BAMFORD, J
    SANDERCOCK, P
    DENNIS, M
    BURN, J
    WARLOW, C
    [J]. LANCET, 1991, 337 (8756) : 1521 - 1526
  • [3] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [4] Predictors of good outcome after intravenous tPA for acute ischemic stroke
    Demchuk, AM
    Tanne, D
    Hill, MD
    Kasner, SE
    Hanson, S
    Grond, M
    Levine, SR
    [J]. NEUROLOGY, 2001, 57 (03) : 474 - 480
  • [5] Tissue plasminogen activator for acute ischemic stroke in clinical practice - A meta-analysis of safety data
    Graham, GD
    [J]. STROKE, 2003, 34 (12) : 2847 - 2850
  • [6] Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
    Grond, M
    Stenzel, C
    Schmülling, S
    Rudolf, J
    Neveling, M
    Lechleuthner, A
    Schneweis, S
    Heiss, WD
    [J]. STROKE, 1998, 29 (08) : 1544 - 1549
  • [7] Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000
    Grotta, JC
    Burgin, WS
    El-Mitwalli, A
    Long, M
    Campbell, M
    Morgenstern, LB
    Malkoff, M
    Alexandrov, AV
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (12) : 2009 - 2013
  • [8] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [9] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [10] Hacke W, 2004, LANCET, V363, P768